Institute of Antibiotics, Huashan Hospital, Fudan University, Shanghai, China.
Department of Hematology, the First Affiliated Hospital of Soochow University, Suzhou, China.
Future Microbiol. 2022 Oct;17:1203-1206. doi: 10.2217/fmb-2022-0093. Epub 2022 Aug 2.
WHAT IS THIS SUMMARY ABOUT?: Invasive aspergillosis (also known as IA) is a type of fungal infection, caused by a species of fungus called , that can be life threatening. Isavuconazole and voriconazole belong to a group of antifungal drugs called triazoles that are recommended for treating IA. In the USA and in Europe, isavuconazole is approved for treating patients with IA. In China, isavuconazole was recently being reviewed for approval for treating patients with IA. This study looked at whether isavuconazole works in the same way in healthy Chinese people as it does in healthy Western people. It also looked to see how well isavuconazole works and how many side effects it has compared with voriconazole in Chinese patients with IA.
WHAT WERE THE RESULTS?: The results of this study showed that healthy Chinese people's bodies processed isavuconazole the same way as healthy Western people's bodies. The amount of drug in people's bodies did not change how well the drug worked or how many side effects there were. Isavuconazole worked as well as and had a similar number of side effects as voriconazole in treating Chinese patients with IA.
WHAT DO THE RESULTS OF THE STUDY MEAN?: These findings show that isavuconazole may be a suitable treatment for Chinese patients with IA using the same dose that is used in Western patients.
这项研究旨在观察伊曲康唑在健康的中国人群中的作用是否与在健康的西方人群中相同。它还观察了伊曲康唑在治疗中国侵袭性曲霉菌病患者方面的疗效以及与伏立康唑相比的副作用发生率。
研究结果表明，健康的中国人体处理伊曲康唑的方式与健康的西方人体相同。药物在人体中的含量不会影响药物的疗效或副作用的发生。伊曲康唑在治疗中国侵袭性曲霉菌病患者方面与伏立康唑疗效相当，副作用发生率也相似。
这些发现表明，伊曲康唑可能是一种适合中国侵袭性曲霉菌病患者的治疗药物，其剂量与西方患者相同。
